首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1140739

全球藥用輔料市場-2022-2029

Global Pharmaceutical Excipients Market - 2022-2029

出版日期: 2022年10月20日 | 出版商:

DataM Intelligence | 英文 170 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

對仿製藥的需求增加是市場增長的驅動力。

在過去十年中，仿製藥行業取得了令人難以置信的連勝，公司獲得了高於平均水平的股東回報。仿製藥是指具有相同用法、劑量、重量、給藥途徑和成本的品牌藥的仿製藥。據印度品牌資產基金會稱，印度是全球製藥行業的新興參與者。印度是世界領先的仿製藥供應國之一，佔全球銷售額的20%，供應全球約60%的免疫需求。印度製藥業在全球的價值約為 420 億美元，並且還在持續增長。例如，2021 年 8 月的印度醫藥市場從 2020 年 7 月的 13.7% 年增長率為 17.7%。就處方藥出口量而言，它也位居世界第12位。印度藥品出口到全球200多個國家，美國是一個重要市場。仿製藥佔全球出口的20%，使其成為全球最大的仿製藥供應商。印度2010財年藥品和藥品的出口額為246億美元，2021財年為244.4億美元。

然而，監管障礙限制了新輔料的開發。缺乏生產和許可輔料的獨立規則阻礙了涉及新型輔料的研發項目。在當前的監管環境下，如果一項新藥申請（NDA）失敗，則賦形劑已經失敗，即使失敗不是因為賦形劑。此外，來自失敗輔料的臨床試驗的證據是無益的。因此，藥品生產企業和輔料生產企業遭受重大經濟損失。製造符合法規要求的新輔料所需的成本和時間對於製造商來說是高得令人望而卻步的，並降低了接受新輔料的可能性。

地理滲透。

在預測期內，歐洲是主要地區。

該研究按地區分析了全球市場的藥用輔料市場，包括北美、歐洲、亞太地區、南美、中東和非洲。

歐洲將在 2021 年主導全球藥用輔料市場。由於各種具有巨大製造能力的製藥巨頭的出現，該地區的輔料消費處於高水平。對新型輔料不斷增長的需求也受到對優質藥物、仿製藥和生物仿製藥的日益依賴的推動。此外，預計歐洲在預測期內的價值將出現顯著增長。

由於其龐大的人口基數，尤其是在印度和中國，預計亞太藥用輔料市場在預測期內將出現快速增長。此外，新興國家醫療設施的擴張、大量仿製藥製造商、政府舉措和專業團體的增加等預計將推動亞太地區藥用輔料市場的增長。

競爭格局。

由於大型醫療公司的存在，藥用輔料市場是一個競爭激烈的市場。為全球市場增長做出貢獻的領先藥用輔料製造商有 Dupont des Nemours、Roquette-Pheles、Ashland World Holdings Ltd.、BASF SE、Evonik Industries AG、Associated British Foods plc、Archer-Daniel-Midland Corporation、Lubrizol Corporation、Kuroda國際、Innophos Holdings 等。領先公司正在為藥用輔料市場的全球增長採取新產品發布和擴張戰略。2022 年 4 月，Ashland將擴大與 Univer 的藥物成分分銷協議。該協議將為 Univer Solutions 在巴西和墨西哥的客戶提供亞甚蘭固體劑型粘合劑和崩解劑、緩釋藥物基質形成劑以及常規和緩釋固體劑型包衣的使用權。該協議結合了兩家專注於可持續發展的公司的優勢和服務，這些公司在拉丁美洲和全球提供基於科學的製藥解決方案。2021 年 12 月，全球植物成分領導者和天然藥用輔料的領先供應商 Roquette 宣布計劃在美國開設新的創新中心，以進一步推進處方藥。2022 年 2 月，Azeris 擴大了與領先的藥用輔料供應商 Roquette 的合作夥伴關係，在印度推出了一系列藥用纖維素產品，加強了其在印度的製藥業務。該合作夥伴關係擴展了 Roquette 的全面產品組合，包括微晶纖維素 (MCC) 和交聯羧甲基纖維素鈉 (CCS) 產品。

COVID-19 的影響將對全球藥用輔料市場產生積極影響。

隨著與 COVID-19 無關的醫療保健設施繼續以正常速度運行，預計全球對藥用輔料的需求將在整個 COVID-19 流行病的出現期間增加。在當前的 COVID-19 大流行之後，藥用輔料市場預計將增長。市場進入者必須專注於解決 COVID-19 大流行帶來的供應鏈挑戰並設計適當的解決方案。

全球藥用輔料市場報告提供了大約 61 個市場數據表、57 個數字和 170 頁的結構。

Market Overview

Pharmaceutical Excipients Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 5.5 % during the forecast period (2022-2029).

Pharmaceutical excipients are harmless compounds used in the production process used in the dosage form of a pharmaceutical product but are not pharmacologically active components. Excipients are often used in drug formulation to provide long-term stabilization, bulk up stable formulations, and aid absorption. They often improve the product's overall protection or reliability during storage or use. Pharmaceutical excipients are being driven by factors such as the growing pharmaceutical industry, advances in functional excipients, the introduction of orphan drugs, and the penetration of biopharmaceuticals.

Market Dynamics: The rise in demand for generic drugs drives market growth.

Over the last decade, the generics sector has had a phenomenal streak, with businesses earning above-average shareholder returns. Generic products are generic versions of branded drugs with the same dosage type, weight, route of delivery, and cost. According to the India Brand Equity Foundation, India is a rising player in the global pharmaceutical sector. India is one of the world's leading generic medication suppliers, accounting for 20% of volume worldwide and supplying about 60% of the global vaccination demand. The Indian pharmaceutical sector is continuously growing at around US$ 42 billion worldwide. For instance, in August 2021, the Indian pharmaceutical market increased by 17.7% annually, up from 13.7% in July 2020. It is the 12th largest exporter of medical goods in the world. Indian drugs are exported to more than 200 countries worldwide, with the US being the key market. Generic drugs account for 20% of the global export volume, making the country the largest provider of generic medicines globally. Indian drug & pharmaceutical exports stood at US$ 24.60 billion in FY22 and US$ 24.44 billion in FY21.

However, regulatory hurdles restrict the development of novel pharmaceutical excipients. The lack of independent rules for excipient manufacturing and clearance is deterring R&D projects involving novel excipients. In the current regulatory environment, if a new drug application (NDA) fails, the excipient still fails, even if the failure is not attributed to the excipient. Furthermore, the evidence from the unsuccessful excipient's clinical trials was useless. The drug and the excipient maker suffer significant financial losses due to this. The cost and time required to produce novel excipients when adhering to regulatory requirements are prohibitively expensive for manufacturers, reducing the likelihood of a novel excipient being accepted.

Market Segmentation: The organic segment is projected to be the dominant segment in the market during the forecast period.

Based on the Product, the pharmaceutical excipients market has been classified into Organic, Inorganic and Others.

Organic dominated the global market in 2019, owing to the wide usage of organic in the majority of pharmaceutical formulations available in the pharmaceutical market. At the same time, organic is expected to present considerable growth in the near future. Natural excipients are primarily used in oral formulations as binders and fillers, which aid segmental growth during the forecast period.

Pharmaceutical excipients are segmented based on formulation, which includes oral, parenteral, topical and others.

The oral segment held a significant market share in the forecast period as oral formulations are the most common route of drug delivery, which supports the segment growth during the forecast period. Moreover, the Topical is expected to project a considerable CAGR during the forecast period. Strong assimilation of topical excipients with liquid APIs and improved patient compliance due to sensorial effects drive this segment's development.

Geographical Penetration: Europe is the dominating region during the forecast period.

Based on geography, the study analyzes the pharmaceutical excipients market in the global market, including North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Europe held a dominant position in the global pharmaceutical excipients market in 2021. Excipient consumption in the region is high due to the emergence of various pharmaceutical behemoths with massive manufacturing capacities. The increased demand for novel excipients is also due to the increasing reliance on superior pharmaceutical drugs, generics, and biosimilars. Moreover, Europe is expected to represent significant growth in terms of value during the forecast period.

The pharmaceutical excipients market for the Asia Pacific is expected to observe rapid growth over the forecast period, backed by the large population base, especially in India and China. Moreover, the developing healthcare facilities, large number of generic manufacturers and rise in government initiatives and specialist communities are expected to augment the growth of the Asia Pacific pharmaceutical excipients market.

Competitive Landscape:

The Pharmaceutical Excipients market is highly competitive, owing to the presence of big medical companies. The key Pharmaceutical Excipients players which are contributing to the growth of the global market include DuPont de Nemours Inc, Roquette Feres, Ashland Global Holdings Inc.., BASF SE., Evonik Industries AG., Associated British Foods plc, Archer Daniels Midland Company, Lubrizol Corporation, Croda International, Innophos Holdings, among others. The major players are adopting new Product launches and expansion strategies for global growth in the Pharmaceutical Excipients market. In April 2022, Ashland expands its distribution deal with Univar for pharma ingredients. Through this agreement, Univar Solutions customers in Brazil and Mexico have access to Ashland's binders and disintegrants for solid dosage forms, matrix formers for modulated release drugs and coatings for regular and modulated release solid dosage forms. This agreement combines the strengths and offerings of two sustainability-focused companies delivering science-based pharmaceutical solutions in Latin America and globally. In December 2021, Roquette, a global leader in plant-based ingredients and a leading provider of naturally-derived pharmaceutical excipients, announced its plan to open a new Innovation Center in the US to further the advancement of prescription drugs. In February 2022, Azelis strengthened its pharmaceutical presence in India by expanding its partnership with Roquette, a leading provider of pharmaceutical excipients, to distribute its pharmaceutical cellulose product range in India. The company expanded its comprehensive product portfolio through this partnership by including Roquette's Microcrystalline Cellulose (MCC) and Croscarmellose Sodium (CCS) products.

COVID-19 Impact: Positive impact on the global pharmaceutical excipients market.

The growth of global demand for pharmaceutical excipients is projected to increase throughout the emergence of the COVID-19 pandemic as non-COVID-related healthcare facilities continue to run at a regular pace. The market for pharmaceutical excipients is expected to grow in the wake of the current COVID-19 pandemic. Market participants must concentrate on solving the supply chain issues raised by the COVID-19 pandemic and designing appropriate solutions to resolve them.

The global pharmaceutical excipients market report would provide an access to approximately 61 market data tables, 57 figures and 170 pages

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

3.1. Market Snippet by Product
3.2. Market Snippet by Functionality
3.3. Market Snippet by Formulation
3.4. Market Snippet by Region

4. Market Dynamics

4.1. Market Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in demand for Generic Drugs
  - 4.1.1.2. Increasing Chronic condition
- 4.1.2. Restraints:
  - 4.1.2.1. Regulatory hurdles restricting the development of novel pharmaceutical excipients
- 4.1.3. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Value Chain Analysis
5.4. PEST Analysis
5.5. Pricing Analysis
5.6. Regulatory Analysis
5.7. Reimbursement Analysis
5.8. Unmet Needs
5.9. Patent Trends

6. COVID-19 Analysis

6.1. Analysis of Covid-19 on the Market
- 6.1.1. Before COVID-19 Market Scenario
- 6.1.2. Present COVID-19 Market Scenario
- 6.1.3. After COVID-19 or Future Scenario
6.2. Pricing Dynamics Amid Covid-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product

7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Segment
7.3. Market Attractiveness Index, By Product Segment
- 7.3.1. Organic*
  - 7.3.1.1. Introduction
  - 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 7.3.2. Inorganic
- 7.3.3. Other

8. By Functionality

8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality Segment
8.3. Market Attractiveness Index, By Functionality Segment
- 8.3.1. Fillers*
  - 8.3.1.1. Introduction
  - 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 8.3.2. Diluents
- 8.3.3. Coatings
- 8.3.4. Disintegrants
- 8.3.5. Others

9. By Formulation

9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation Segment
9.3. Market Attractiveness Index, By Formulation Segment
- 9.3.1. Oral*
  - 9.3.1.1. Introduction
  - 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
- 9.3.2. Parenteral
- 9.3.3. Topical
- 9.3.4. Others

10. By Region

10.1. Introduction
10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
10.3. Market Attractiveness Index, By Region
10.4. North America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. U.S.
  - 10.4.6.2. Canada
  - 10.4.6.3. Mexico
10.5. Europe
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. Germany
  - 10.5.6.2. U.K.
  - 10.5.6.3. France
  - 10.5.6.4. Italy
  - 10.5.6.5. Spain
  - 10.5.6.6. Rest of Europe
10.6. South America
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.6.6.1. Brazil
  - 10.6.6.2. Argentina
  - 10.6.6.3. Rest of South America
10.7. Asia Pacific
- 10.7.1. Introduction
- 10.7.2. Key Region-Specific Dynamics
- 10.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 10.7.6.1. China
  - 10.7.6.2. India
  - 10.7.6.3. Japan
  - 10.7.6.4. Australia
  - 10.7.6.5. Rest of Asia Pacific
10.8. Middle East and Africa
- 10.8.1. Introduction
- 10.8.2. Key Region-Specific Dynamics
- 10.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product
- 10.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Functionality
- 10.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Formulation
- 10.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. DuPont de Nemours Inc*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Key Highlights
- 12.1.4. Financial Overview
12.2. Roquette Feres.
12.3. Ashland Holdings Inc..
12.4. BASF SE.
12.5. Evonik Industries AG.
12.6. Associated British Foods plc
12.7. Archer Daniels Midland Company
12.8. Lubrizol Corporation.
12.9. Croda International
12.10. Innophos Holdings (LIST NOT EXHAUSTIVE)